A functional Ser413/Ser413 PAI-2 polymorphism is associated with susceptibility and damage index score in systemic lupus erythematosus

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 2, 2009, Pages 233-238

  Palafox Sénchez, Claudia A ^a   Vézquez Del Mercado, Mónica ^a   Orozco Barocio, Gerardo ^b   García De La Torre, Ignacio ^b   Torres Carrillo, Norma ^a   Torres Carrillo, Nora M ^a   Illades Aguiar, Berenice ^c   Muñoz Valle, José F ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL GENERAL DE OCCIDENTE   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE GUERRERO   (Mexico)

Author keywords

Plasminogen activator inhibitor 2; Polymorphism; RA; SLE

Indexed keywords

ANTIRHEUMATIC AGENT; CYSTEINE; DNA FRAGMENT; NONSTEROID ANTIINFLAMMATORY AGENT; SERINE; PLASMINOGEN ACTIVATOR INHIBITOR 2;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ALLELES; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 2; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 64549131747     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607308868     Document Type: Article

References (19)

1. Sawalha AH, Harley JB Antinuclear autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol. 2004 ; 16: 534-540. (Pubitemid 39128320)
2. Salazar-Paramo M., Garcia de la Torre I., Fritzler MJ, et al. Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis. Lupus. 1996 ; 5: 275-278. (Pubitemid 26306235)
3. Goldring SR Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology. 2003 ; 42 (suppl 2). ii11 - ii16.
4. Kohler HP, Grant PJ Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000 ; 342: 1792-1799.
5. Buyru N., Altinisik J., Gurel CB, et al. PCR-RFLP detection of PAI-2 variants in Myocardial Infarction. Clin Appl Thromb Hemost. 2003 ; 9: 333-336. (Pubitemid 37414124)
6. Kruithof Egbert KO, Baker MS, Bunn CL Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood. 1995 ; 86: 4007-4024.
7. Vézquez-Del Mercado M., García-Cobian TA, Muñoz-Valle JF, et al. Genotype Ser413/Ser of PAI-2 polymorphism Ser413/Cys is associated with anti-phospholipid syndrome and systemic lupus erythematosus in a familial case: comparison with healthy controls. Scand J Rheumatol. 2007 ; 36: 206-210. (Pubitemid 47174551)
8. Arnett FC, Edworthy SM, Bloch DA The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 ; 31: 315-324.
9. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277.
10. Guzmén J., Cardiel MH, Arce-Salinas A., et al. Measurement of disease activity in systemic lupus erythematosus: prospective validation of 3 clinical indices. J Rheumatol. 1992 ; 19: 1551-1558.
11. Gladman D., Ginzler E., Goldsmith C., et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 363-369. (Pubitemid 26085211)
12. Cardiel MH, Abello-Banfi M., Ruiz-Mercado R., et al. How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). Clin Exp Rheumatol. 1993 ; 11: 117-121. (Pubitemid 23155978)
13. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 ; 38: 44-48.
14. Ruiz-Quezada S., Vézquez-Del Mercado M., Parra-Rojas I., et al. Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico. Association with biochemical and hematological parameters. Annales de Génétique. 2004 ; 47: 155. (Pubitemid 38748498)
15. Miller SA, Dykes DD, Pulesky HF A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988 ; 16: 1215.
16. Foy CA, Grant PJ PCR-RFLP detection of PAI-2 gene variants: prevalence in ethnic groups and disease relationship in patients undergoing coronary angiography. Thromb Haemost. 1997 ; 77: 955-958. (Pubitemid 27239121)
17. Hahn BH Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med. 2003 ; 349: 2379-2380. (Pubitemid 37542984)
18. Lopez LR, Salazar-Paramo M., Palafox-Sanchez C., et al. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus. 2006 ; 15: 80-86. (Pubitemid 43345332)
19. Roman MJ, Shanker BA, Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2399-2406. (Pubitemid 37542988)